Abu Dhabi’s Advanced Technology Research Council launches ‘AI71’: New AI Company Pioneering Decentralised Data Control for Companies & Countries
In an era of rapid advancements across artificial intelligence (AI), Abu Dhabi’s Advanced Technology Research Council (ATRC) is making yet another bold stride with the launch of its new AI company, AI71. The entity builds on the Technology Innovation Institute’s (TII) Falcon generative AI models and will focus on multi-domain specializations while offering unprecedented AI data control options for companies and countries looking to self-host for greater privacy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231128549220/en/
H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council launches AI71 along with H.E Faisal Al Bannai, Secretary General, Advanced Technology Research Council (Photo: AETOSWire)
The new AI powerhouse was launched by H.H. Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Chairman of the Abu Dhabi Executive Council, in the presence of several ministers and representatives of leading multinational technology companies.
While ATRC’s Technology Innovation Institute developed the Falcon 7B, 40B, and 180B large language models (LLMs), it will be ATRC’s VentureOne subsidiary that takes AI71 to market across multiple domains, starting with the medical, educational, and legal sectors. Enabling access to vast storehouses of anonymized data in these verticals – representing a rich and diverse demographic - AI71 will offer a critical differentiator over other serious AI markets today – namely, the UAE’s highly digitized and comparatively mature e-infrastructure.
At a time where innovation often outpaces regulatory frameworks, the UAE government's swift decision-making structure uniquely positions the new company to leverage its responsible AI advancements globally, bypassing the lengthy processes often associated with such developments.
Through partnerships and collaborations, AI71 will enable clients to deploy its AI models and benefit from access to sophisticated data reservoirs to ensure outstanding generative AI performance. More importantly, AI71 will enable decentralized data ownership, allowing clients to retain control of their own data. This offering will set new standards for privacy and security, serving as a differentiator for AI projects where data sovereignty is critical. This is a game-changing option for AI accessibility, particularly for enterprises, large corporations, and foreign government entities keen to ensure that their data remains private.
AI71 will be built on a pro-innovation, whole-of-society approach, and on the premise that AI technology should not remain in the hands of a few but be accessible to more people to foster creative innovation. The new AI company is focused on deepening the credentials of Abu Dhabi and the wider UAE as a serious AI contender, and in doing so, signposting the coming of age of the country’s knowledge economy.
H.E. Faisal Al Bannai, Secretary General of the Advanced Technology Research Council, said: "In the UAE, collaboration is more than a practice - it's embedded in our DNA. Our Falcon generative AI models, at the heart of AI71, empower developers, companies, and countries, and grants them autonomy to steer their own data destiny. With access to the UAE’s centralized datasets, the deliberate commercialization of our AI models across diverse sectors stands as a pivotal element in our AI71 roadmap. While we explore this avenue, we also make a firm commitment to perpetually open sourcing Falcon AI models, because only by democratizing these precious data resources do we truly benefit all of society.”
The first of AI71’s cutting-edge specializations will have a medical focus and seek to transform capabilities in diagnosis and decision-making, significantly changing the accuracy and time spent on each patient.
The educational and legal sectors are also to gain value from AI integration and enhancements - impacting each domain with nuanced benefits that lead to new solutions to support societal development.
AI71 is collaborating with seven partners across the ecosystem. These encompass the Department of Government Enablement – Abu Dhabi, which centralizes over 30 government entities through digitization; the Office of Artificial Intelligence, Digital Economy, and Remote Work Applications, to support with broader adoption; World Wide Technology to co-develop integrated on-premise AI solutions; CNTXT to provide data labeling and annotation services; Hub71 to attract and scale tech and AI startups; PwC Middle East to address customer use cases; and AWS to supply compute power capacity.
With AI influencing how we live and work for the foreseeable future, the newly established company is looking to grow its offerings for enterprises based on industry demand and facilitate the widespread diffusion of AI across the broader economy. AI71 presents an opportunity to lead a step change and drive an AI-first ecosystem in the UAE and beyond.
As AI71 makes an impact across enterprises, industries, and governments, VentureOne will introduce new specializations to meet growing demand from various sectors.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231128549220/en/
Contact information
Jennifer Dewan, Senior Director of Communications
jennifer.dewan@tii.ae.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
